You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A licence to vape: Is it time to trial of a nicotine licensing scheme to allow Australian adults controlled access to electronic cigarettes devices and refill solutions containing nicotine?
|
|---|---|
| Published in |
International Journal of Drug Policy, March 2015
|
| DOI | 10.1016/j.drugpo.2015.02.003 |
| Pubmed ID | |
| Authors |
Coral Gartner, Wayne Hall |
| Abstract |
Australia has some of the most restrictive laws concerning use of nicotine in e-cigarettes. The only current legal option for Australians to legally possess and use nicotine for vaping is with a medical prescription and domestic supply is limited to compounding pharmacies that prepare medicines for specific patients. An alternative regulatory option that could be implemented under current drugs and poisons regulations is a 'nicotine licensing' scheme utilising current provisions for 'dangerous poisons'. This commentary discusses how such a scheme could be used to trial access to nicotine solutions for vaping outside of a 'medicines framework' in Australia. |
X Demographics
The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 4 | 31% |
| United States | 2 | 15% |
| Spain | 1 | 8% |
| Unknown | 6 | 46% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 69% |
| Practitioners (doctors, other healthcare professionals) | 4 | 31% |
Mendeley readers
The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ireland | 1 | 2% |
| Unknown | 60 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 9 | 15% |
| Student > Master | 8 | 13% |
| Student > Ph. D. Student | 6 | 10% |
| Researcher | 5 | 8% |
| Student > Doctoral Student | 4 | 7% |
| Other | 14 | 23% |
| Unknown | 15 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Social Sciences | 8 | 13% |
| Medicine and Dentistry | 6 | 10% |
| Psychology | 5 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 7% |
| Nursing and Health Professions | 4 | 7% |
| Other | 15 | 25% |
| Unknown | 19 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 September 2019.
All research outputs
#3,386,542
of 25,446,666 outputs
Outputs from International Journal of Drug Policy
#1,162
of 3,053 outputs
Outputs of similar age
#41,047
of 271,956 outputs
Outputs of similar age from International Journal of Drug Policy
#15
of 34 outputs
Altmetric has tracked 25,446,666 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,053 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 24.6. This one has gotten more attention than average, scoring higher than 61% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 271,956 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.